Rocket Pharmaceuticals Announces Participation in a Fireside Chat at the Leerink Partners 7th Annual Global Healthcare Confer...
February 07 2018 - 7:00AM
Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a
leading U.S.-based multi-platform gene therapy company, today
announced that Gaurav Shah, M.D., Chief Executive Officer and
President of Rocket, will participate in a fireside chat at the
Leerink Partners 7th Annual Global Healthcare Conference in New
York City. The fireside chat will take place on Wednesday, February
14, 2018, at 2:00 p.m. Eastern Time (ET).
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an
emerging, clinical-stage biotechnology company focused on
developing first-in-class gene therapy treatment options for rare,
undertreated diseases. Rocket’s multi-platform development approach
applies the well-established lentiviral vector (LVV) and
adeno-associated viral vector (AAV) gene therapy platforms.
Rocket's lead clinical program is a LVV-based gene therapy for the
treatment of Fanconi Anemia (FA), a difficult to treat genetic
disease that leads to bone marrow failure and potentially cancer.
Preclinical studies of additional bone marrow-derived disorders are
ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte
Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis
(IMO). Rocket is also developing an AAV-based gene therapy program
for an undisclosed rare pediatric disease. For more information
about Rocket, please visit www.rocketpharma.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180207005145/en/
Claudine Prowse, Ph.D.SVP Corporate Development and IRORocket
Pharma, Inc.The Alexandria Center for Life Science430 East 29
Street, Suite 1040New York, NY 10016cp@rocketpharma.com
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Apr 2023 to Apr 2024